In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Data from Boehringer Ingelheim’s Phase II apecotrep study was published in The Lancet and presented at the 2025 ASN’s Kidney Week ...

In its new incarnation, apecotrep has been shown to reduce protein in the urine (proteinuria) – a biomarker for kidney disease – in people with primary focal segmental glomerulosclerosis (FSGS), a ...

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Vertex is running a phase 2 trial of inaxaplin in APOL1-mediated kidney diseases, including some forms of FSGS. The phase 3 ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

By placing the cells on surfaces patterned with fractal shapes that mimic natural structures in the kidney, the team ...

Our previous studies using puromycin aminonucleoside (PAN) established that podocyte damage leads to glomerular growth arrest during development and glomerulosclerosis later in life. This study ...